Literature DB >> 19651393

Treatment of RSV bronchiolitis: drugs, antibiotics.

Ian Mitchell1.   

Abstract

RSV bronchiolitis is one of the most common reasons for hospital admission and for visits to emergency departments for children, and at least half of affected infants will have subsequent episodes of respiratory illness. Despite this, there are wide variations in management. Initial assessment of respiratory status should include a measure of oxygenation and oxygen should be given when there is clinical evidence of respiratory distress even before full assessment is completed. Fluid and nutritional status should also be assessed early and decisions made about use of intravenous fluids, nasogastric feeding, or maintenance of frequent feeds orally. Given the lack of evidence on all drug therapies for bronchiolitis, clinicians should carefully evaluate treatments for their ability to reduce symptoms, decrease length of hospital stay and reduce sequelae. Furthermore, clinicians should monitor antibiotic use carefully and develop a strategy to change current physician practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19651393     DOI: 10.1016/S1526-0542(09)70007-7

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  3 in total

1.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

Review 2.  Impact of respiratory syncytial virus: the nurse's perspective.

Authors:  Marianne Bracht; Debbie Basevitz; Marilyn Cranis; Rose Paulley
Journal:  Drugs R D       Date:  2011-09-01

3.  Medical retrieval and needs of infants with bronchiolitis: an analysis by gestational age.

Authors:  Paul F Fleming; Susie Richards; Kelly Waterman; Peter G Davis; C Omar F Kamlin; Michael Stewart; Jenni Sokol
Journal:  J Paediatr Child Health       Date:  2012-12-11       Impact factor: 1.954

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.